TEST NAME
– FLT3 (ITD, D835Y)
ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ
ABOUT TEST
– Activating mutations of the fms-related tyrosine kinase 3 (FLT3) gene occur in about a third of cases of AML-NK and have prognostic significance in the context of current AML therapies. The most common type of FLT3 mutation is the in-frame internal tandem duplications (FLT3-ITD) where a portion of the gene is duplicated leading to constitutive signaling from the kinase. AML patients in the intermediate-risk category whose blast cells harbor FLT3-ITD mutations have a higher risk of relapse and worse prognosis than those without following standard chemotherapeutic regimens.
It is recommended that patients with AML be screened for the presence of FLT3 mutations before induction therapy. Induction therapy is unlikely to be altered due to FLT3 mutation status; however, knowing the FLT3 mutation status can help stratify patients into groups that will receive different post-remission treatments. Currently there are several small molecule inhibitors of FLT3 in clinical trials. Identifying patients with FLT3 mutations may make patients eligible for these research therapies.
ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ
GENES TESTED
–
ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ
SAMPLE REQUIREMENTS
– EDTA
ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ
TAT
– 14
ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ
Related Tests
–
ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ